Zeng Yu, Han Rui-Ting, Zhou Qing-Wei
Henan University of Chinese Medicine Zhengzhou 450046, China.
the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450099, China.
Zhongguo Zhong Yao Za Zhi. 2021 Aug;46(15):3960-3969. doi: 10.19540/j.cnki.cjcmm.20210406.402.
This study aimed to explore the mechanism of Tanreqing Injection in the treatment of acute lung injury(ALI) based on network pharmacology and molecular docking. The active components and action targets of Tanreqing Injection were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP), PubChem, and SwissTargetPrediction databases, as well as available literature reports. The ALI-related targets were obtained from the GeneCards database and then mapped with Tanreqing Injection targets. Following the construction of "drug-component-potential target" network with Cytoscape 3.6.1, the potential targets were input into STRING to yield the protein-protein interaction(PPI) network, which was plotted using Cytoscape 3.6.1. Then the screened key targets were subjected to gene ontology(GO) and Kyoto encyclopedia of genes and genomes(KEGG) enrichment analysis based on DAVID database. The top three key targets RAC-alpha serine/threonine-protein kinase(AKT1), albumin(ALB) and interleukin-6(IL6) were docked to the top three key compounds by PyMOL and AutoDock vina. A total of 58 active components of Tanreqing Injection, 597 corresponding targets and 503 common targets shared by Tanreqing Injection and ALI were fi-gured out, with the key targets AKT1, ALB and IL6 involved. GO and KEGG enrichment analysis yielded 1 445 biological processes and 148 signaling pathways, respectively. Molecular docking verified a good binding ability of the top three key targets to the top three key compounds. The analysis based on network pharmacology and molecular docking uncovered that Tanreqing Injection directly or indirectly regulated the pulmonary capillary endothelial cells and alveolar epithelial cells via anti-inflammation, thus alleviating ALI.
本研究旨在基于网络药理学和分子对接技术探索痰热清注射液治疗急性肺损伤(ALI)的机制。从中药系统药理学数据库和分析平台(TCMSP)、PubChem以及SwissTargetPrediction数据库,还有现有文献报道中检索痰热清注射液的活性成分和作用靶点。从GeneCards数据库获取ALI相关靶点,然后与痰热清注射液靶点进行映射。使用Cytoscape 3.6.1构建“药物-成分-潜在靶点”网络后,将潜在靶点输入STRING以生成蛋白质-蛋白质相互作用(PPI)网络,并用Cytoscape 3.6.1绘制该网络。然后基于DAVID数据库对筛选出的关键靶点进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析。通过PyMOL和AutoDock vina将前三个关键靶点RAC-α丝氨酸/苏氨酸蛋白激酶(AKT1)、白蛋白(ALB)和白细胞介素-6(IL6)与前三个关键化合物进行对接。共确定了痰热清注射液的58种活性成分、597个相应靶点以及痰热清注射液与ALI共有的503个共同靶点,其中涉及关键靶点AKT1、ALB和IL6。GO和KEGG富集分析分别产生了1445个生物学过程和148条信号通路。分子对接验证了前三个关键靶点与前三个关键化合物具有良好的结合能力。基于网络药理学和分子对接的分析发现,痰热清注射液通过抗炎直接或间接调节肺毛细血管内皮细胞和肺泡上皮细胞,从而减轻ALI。